Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Governance Other
confidence 85%
filed 2026-07-10
The 6-K discloses shareholder approval on July 7, 2026, at the 2026 Annual General Meeting to increase authorized share capital from approximately 3.3 million to 50 million Class A ordinary shares—a 14-fold increase. This is a governance event (shareholder vote on capitalization) that materially affects the company's capital structure and future dilution potential, though it does not fit the specific `shareholder_vote_results` category (which typically reports vote outcomes on discrete proposals like director elections or compensation plans). The increase in authorized shares is a material structural change that would affect investor assessment of dilution risk.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-10
Item 1.01
On July 9, 2026, Faraday Future entered into an Amended and Restated Securities Purchase Agreement materially restructuring the terms of its July 2025 financing ($82 million convertible notes). The amendment restructures the second closing into eight separate tranches tied to $5 million funding milestones, eliminates warrant issuances for most investors, removes registration obligations, and includes termination of warrant agreements cancelling 5.36 million warrants (with cumulative warrant cancellations of approximately 49.9 million shares since 2025), materially reducing shareholder dilution and reshaping the company's capital structure and financing obligations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-10
EX-99.1
This exhibit is a Securities Purchase Agreement dated July 10, 2026, under which VisionSys AI Inc is offering up to $91,750,000 of Ordinary Shares (represented by ADSs) at USD 0.000734 per share to multiple purchasers. The agreement explicitly relies on Section 4(a)(2) of the Securities Act and Regulation S exemptions from registration, indicating an unregistered private placement. This is a material dilutive issuance of equity securities to raise capital outside the registered public market.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-10
Helport AI entered into an at-the-market (ATM) sales agreement with Lake Street Capital Markets on July 10, 2026, permitting the company to offer and sell up to $9,550,000 of ordinary shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, structured as an ATM offering. The agreement grants the sales agent a 3.0% commission and customary indemnification rights, and the shares are registered under Form F-3 (Registration Number 333-294622). Such capital-raising activities are material to investors assessing the registrant's financing strategy and potential shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-10
Item 1.01
The filing discloses entry into a letter agreement modifying a Common Stock Purchase Agreement with Roth Principal Investments dated June 30, 2026. The adjustment of the purchase price discount to 5.0% of VWAP for pre- and post-market purchases indicates a private equity investment involving issuance of common stock at a discount to market price. This is a classic dilutive issuance structure typical of PIPE or equity financing arrangements, material to investors assessing capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-10
The filing discloses the consummation of Viking Acquisition Corp. II's initial public offering on July 6, 2026, involving the issuance of 23,000,000 units at $10.00 per unit ($230 million gross proceeds) and 610,000 private placement units ($6.1 million gross proceeds). While this is technically an IPO rather than a private placement, the core event is the creation of new equity securities (units, ordinary shares, and warrants) that dilute existing shareholders. The private placement component (610,000 units to the Sponsor and underwriter Cohen) is explicitly unregistered under Section 4(a)(2) of the Securities Act, fitting the dilutive_issuance category. The IPO itself, though registered, represents a material capital-raising event through equity issuance.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 82%
filed 2026-07-10
Item 5.02
HeartSciences amended the employment agreement of Danielle Watson (CFO) and granted her 25,000 RSUs in connection with a pending merger. The amendments modify severance provisions (six months base salary, COBRA, 100% acceleration of unvested equity), add discretionary performance bonus eligibility, and establish vesting conditions tied to the merger closing and continued employment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-10
Item 1.01
This Item 1.01 discloses entry into a material definitive agreement—specifically, a second amendment to the Business Combination Agreement between Plum IV and Controlled Thermal Resources Holdings Inc. The amendment materially modifies the merger consideration (reducing valuation from $4.5B to $3.15B), earnout structure (reducing from 100M to 70M shares), and closing timeline (extending to April 30, 2027). These are substantive changes to a material acquisition transaction that would significantly affect investor assessment of the deal's economics and timing.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-10
Item 8.01
The disclosure centers on a listing compliance issue: NYSE American advised that the Acquisition and Line of Credit trigger Section 712 stockholder approval requirements because the Conversion Shares equal 20% or more of outstanding shares. The Company cancelled 1,013,637 Conversion Shares on July 10, 2026 to regain compliance pending shareholder approval. While the underlying M&A activity occurred earlier, this Item 8.01 disclosure is primarily a governance event—a shareholder approval requirement and listing compliance matter—rather than the M&A activity itself (which was disclosed in the June 5 8-K).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-10
Item 8.01
The filing discloses that Nasdaq notified the Company on May 21, 2026, that it was no longer in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Although the Company raised $4.2 million in a July 1, 2026 offering and believes it now satisfies the requirement, Nasdaq will continue monitoring compliance, and the Company "may be subject to delisting" if it does not evidence compliance by its September 30, 2026 Form 10-Q. This is a classic delisting-risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-10
Item 1.01
Silo Pharma entered into securities purchase agreements on July 9, 2026, for a private placement of 619,965 shares of common stock (or pre-funded warrants), Series A-3 and A-4 warrants, raising approximately $4 million upfront with potential additional proceeds of ~$7.7 million upon warrant exercise. The unregistered securities were issued under Section 4(a)(2) and Regulation D exemptions, with a registration rights agreement for resale.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-10
Royal Bank of Canada issued $2.3 billion in aggregate principal amount of Senior Global Medium-Term Notes across three tranches (4.652% fixed/floating due 2029, floating rate due 2029, and 4.950% fixed/floating due 2032) pursuant to its shelf registration statement. This constitutes creation of direct financial obligations and is a material debt issuance event.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-10
EX-99.1
This news release announces that independent proxy advisory firms (including ISS) have recommended shareholders vote FOR an arrangement resolution approving Equinox Gold's acquisition of all issued and outstanding common shares of Orla under a court-approved plan of arrangement dated May 12, 2026. The disclosure concerns a material acquisition/change of control transaction, with the special shareholder meeting scheduled for July 22, 2026. This is a discrete M&A event requiring shareholder approval, not a periodic report or routine governance matter.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-10
EX-99.1
BTQ announced completion of the design of a next-generation QCIM + PUF security chip in collaboration with ICTK, with production preparation underway and test chips expected by year-end. This represents a material operational and product-development milestone for a quantum-security semiconductor company, reflecting progress on a key commercialization pathway. While not a discrete M&A transaction, earnings event, or governance matter, it is a significant strategic product milestone that would affect a reasonable investor's assessment of BTQ's execution and market positioning in quantum-era security semiconductors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-10
Nu Holdings announces that its Mexican subsidiary Nubank México has received final Operations Authorization from the CNBV to commence operations as a multiple bank, completing a transformation process first announced in April 2025. This represents a material operational and regulatory milestone enabling expansion of credit, payments, and savings products in Mexico, a key market for the company's growth strategy.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-10
The 6-K discloses the election of Mr. Alessandro de Castro Melo to the position of Chief Engineering, Technology and Innovation Officer by the Board of Directors on July 10, 2026. This is a material executive appointment to a named officer position, approved by the Board following recommendation by the People and Organization Committee, with a term extending to 2028.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-10
The 6-K body discloses a Board of Directors approval of a distribution of Interest on Equity (a form of dividend under Brazilian law) in the gross amount of R$ 2,000,000,000.00 (approximately R$ 1,650,000,000.00 net after tax withholding), with per-share amounts specified for common, preferred, and unit holders. The distribution is material to shareholders and investors as it represents a significant capital return and affects the total mix of information about the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-10
The Board of Directors approved the declaration and payment of Interest on Company's Equity (a form of dividend distribution under Brazilian law) in the gross amount of R$ 2,000,000,000.00 (approximately R$ 0.25 per common share), payable on August 6, 2026. This is a material capital distribution to shareholders that would affect investor assessment of the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-10
Item 5.02
KBR amended and restated severance and change-in-control agreements for six named executive officers, including the CEO and CFO. The amendments materially enhance severance benefits (increasing the cash severance multiple for non-CEO officers from 1.0x to 1.5x base salary plus target bonus), expand the definition of "Good Reason" to include material diminution of compensation or authority, revise "Cause" definitions with notice and cure processes, and add pro-rata vesting provisions for RSUs and equity awards. These are compensatory arrangements that would affect investor assessment of executive retention costs and incentive structures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-07-10
Item 8.01
The disclosure centers on the results of the Fund's Annual Meeting held June 18, 2026 (adjourned to July 10, 2026), where shareholders elected two Class I Trustees (Brian R. Bruce and John H. Alban) and approved a new investment advisory agreement with Cushing Asset Management, LP. While the section also describes a change of control of the Adviser and entry into the New Advisory Agreement, the primary event disclosed is the shareholder vote and its outcomes, which is material to investors as it affects Fund governance and advisory arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-07-10
Item 8.01
The disclosure centers on the results of the Fund's Annual Meeting held June 18, 2026 (adjourned to July 10, 2026), where shareholders elected two Class II Trustees (Andrea N. Mullins and John H. Alban) and approved a new investment advisory agreement with Cushing® Asset Management, LP. While the section also describes a change of control of the Adviser (NXG Cushing acquiring a 62% interest from founder Jerry V. Swank), the primary 8-K disclosure is the shareholder vote results and approval of the new advisory agreement. The change of control is disclosed as context for why the new agreement was necessary, but the material event triggering the 8-K filing is the shareholder action.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-10
Item 7.01
The company announced a strategic transformation into an AI infrastructure platform, including a ticker symbol change to 'AZIO' (effective July 13, 2026) and a $27.9 million AI infrastructure hosting agreement with Power Champion, scalable to $100 million, representing the company's first long-term contracted AI hosting relationship.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-10
Item 8.01
The Board appointed Chris Young, the existing CEO and director, as Chairman of the Board effective July 7, 2026, concentrating additional board leadership responsibility in the existing chief executive.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-10
Item 8.01
The filing discloses that Autonomix Medical received a deficiency letter on January 14, 2026 for failing the Nasdaq Bid Price Rule (stock below $1.00 per share for 30 consecutive business days), which triggered delisting risk. Although the company subsequently regained compliance by July 9, 2026, the core event disclosed is the prior delisting threat and its resolution. This is material to investors as it reflects the company's historical struggle to maintain listing standards and demonstrates the company was at material risk of delisting.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-10
Item 2.02
Art's-Way Manufacturing issued a press release on July 9, 2026 announcing financial results for the three- and six-month periods ended May 31, 2026, disclosing consolidated sales increases of 23.9% and 26.3% respectively, operating income improvement of 20.2% for the six-month period, and segment-level performance metrics. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and operational trends.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-10
Item 8.01
The Board authorized management to "review, consider and pursue strategic alternatives" explicitly including "a merger or disposition of all of its assets" and "selling certain assets, including one or more of its operating businesses." While no transaction has been completed, the authorization to actively pursue M&A activity and strategic transactions is itself a material disclosure that would affect investor assessment of the company's future direction and potential changes to its capital structure or business composition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-10
Item 5.02
George Holding's resignation from the Board of Directors of Trump Media & Technology Group Corp., effective immediately on July 6, 2026, constitutes a director departure. The filing explicitly states his resignation from the Board and all committees, with no dispute cited. Director changes are material to investors' assessment of governance and board composition.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-10
Item 3.01
GeoVax Labs received a notice from Nasdaq on July 7, 2026, that it failed to meet the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) and does not meet alternative compliance metrics. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a direct notice of failure to satisfy a continued listing rule, the core definition of Item 3.01 delisting_risk.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-07-10
Item 4.01
This is a clear auditor change under Item 4.01. HL&B resigned as the Company's independent registered public accounting firm on July 8, 2026, and CohnReznick was appointed as the new auditor on the same date. The filing explicitly discloses the resignation and appointment, with no adverse opinions, disagreements, or reportable events noted, indicating a routine transition driven by HL&B's asset acquisition by CohnReznick.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-10
Item 2.01
Skillsoft completed the sale of its Global Knowledge Training LLC business to an affiliate of Enduring Ventures on July 6, 2026, for approximately $5.4 million in initial consideration plus $10.0 million in deferred consideration. This material disposition of a business unit significantly affects the registrant's asset base and future revenue streams.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-10
Item 7.01
The filing discloses adjournment of a special stockholder meeting called to vote on the "Asset Sale Proposal" — approval of the sale of substantially all of the Company's assets to Trademark Global, LLC pursuant to an Asset Purchase Agreement dated April 27, 2026. Although the vote was not completed due to insufficient votes at the time of the Special Meeting, the disclosure centers on a material acquisition/disposition event (sale of substantially all assets), which is a change-of-control transaction requiring Item 1.01 or 2.01 disclosure. The adjournment is procedural; the underlying event is the proposed asset sale itself.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-10
Item 8.01
United Health Products announced an agreement with NAMSA, a contract research organization, to serve as regulatory sponsor of a clinical study for CelluSTAT Hemostatic Gauze in connection with the company's FDA Premarket Approval application. This is a material operational and strategic milestone—the establishment of a collaboration to advance a critical product through FDA approval—but does not fit the specific categories of M&A activity, debt issuance, workforce reduction, or other named event types. The disclosure centers on a material business partnership and regulatory strategy development.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-07-10
Item 2.01
SUIC Worldwide Holdings completed the acquisition of 51% of Vision Renu Corporation on July 10, 2026, in exchange for 30 million shares (approximately 35% fully-diluted ownership), resulting in Vision Renu becoming a wholly-owned subsidiary and triggering a significant change of control of SUIC with reconstitution of its Board of Directors and appointment of Vision Renu's Chairman as SUIC's new CEO.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-07-10
Item 1.01
The filing discloses entry into a material definitive agreement, but provides insufficient substantive details regarding the agreement's nature, parties, terms, or business purpose to classify it into a specific event category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-10
Item 3.02
The Company exchanged 1,134 shares of Series B Preferred Stock (aggregate stated value $1,134,000) for 8,203,075 shares of common stock in unregistered transactions with Streeterville Capital, LLC on July 8-9, 2026, conducted under Section 3(a)(9) exemption. This is a classic dilutive equity issuance that materially increases common share count and would significantly affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-07-10
Item 2.05
The disclosure centers on a Board-approved plan to discontinue revenue-generating operations (alcohol monitoring hardware and software) effective July 31, 2026, including workforce reduction (three employees terminated in June 2026), manufacturing cessation, and lease termination. The company estimates ~$50,000 in exit costs and expects to reduce annual operating costs by ~$1.2 million. This is a material operational restructuring with associated exit costs disclosed under Item 2.05, the standard item for workforce reductions and disposal activities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-10
The filing discloses settlement and cooperation agreements with former management members in connection with a "Compliance and Restitution" initiative involving recovery of improperly issued equity and assets, with coordination among 25 investor parties for "contemplated legal actions." The surrender and cancellation of 455,496 shares (13.7M pre-split) represents material restitution tied to historical corporate misconduct under Board review. While no litigation has yet been filed, the disclosure centers on settlement arrangements, cooperation agreements, and anticipated legal actions arising from historical transactions, which constitutes material litigation-related activity.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-10
EX-99.1
The exhibit announces that Basel Medical Group has regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on January 22, 2026. The company's shares had fallen below the $1.00 minimum bid price threshold but have now maintained $1.00 or greater for 10 consecutive business days. This disclosure directly addresses a delisting risk — the company was previously out of compliance with a continued listing standard and has now cured that deficiency. Material to investors as it resolves an immediate threat to continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-10
The filing discloses a stock dividend declaration by the Board of Directors on July 9, 2026, whereby holders of Series B Preferred Stock will receive shares of Common Stock based on accrued and unpaid dividends, with approximately 80,463 shares expected to be issued and payment scheduled for July 29, 2026. This is a material dividend distribution event requiring 8-K disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-10
The filing discloses positive preclinical study results for MIRA-55, a lead drug candidate, demonstrating favorable oral bioavailability and tissue distribution. This is a material operational/development milestone for a clinical-stage pharmaceutical company, as it advances a key pipeline asset and supports continued development strategy. The event does not fit earnings_release (no financial results), but represents a significant product development achievement material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-10
Fast Track Group entered into a non-binding memorandum of understanding with Sony Music Entertainment Malaysia for a strategic joint venture partnership to promote artists across Southeast Asia. This is a material operational/strategic partnership announcement that does not fit a specific named category (not M&A, not a discrete contract milestone, but a significant strategic collaboration). The non-binding nature and lack of financial terms disclosed suggest this is an early-stage partnership announcement rather than a completed transaction, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-07-10
EX-99.1
Fast Track Group announced the successful closing of a $1.5 million senior secured convertible note financing with an institutional investor, plus a $20 million equity line of credit. This constitutes creation of new direct financial obligations under Item 2.03 (Debt Issuance). The convertible note structure and ELOC are material capital-raising transactions that would affect a reasonable investor's assessment of the company's financial position and dilution risk.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-10
EX-99.1
This announcement discloses a 35-for-1 share consolidation approved by shareholders at an extraordinary general meeting on June 12, 2026, effective July 20, 2026. While the consolidation is a capital structure change, it is fundamentally a governance matter—a shareholder-approved corporate action affecting share structure and trading mechanics. The stated purpose is to regain compliance with Nasdaq's minimum bid price requirement, making it material to investors assessing the company's listing status and capital structure, though it does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results (which would apply to voting results, not the announcement of an approved action).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-10
The filing discloses a product enhancement—a third-generation upgrade to NOMAD's Voyager mobile energy storage fleet that increases capacity by up to 56% without changing footprint or deployment time. This is a material operational and strategic development for a company focused on AI energy infrastructure, announced via Item 7.01 (Regulation FD Disclosure) with a press release. While not a named event type (not M&A, not a contract, not a regulatory milestone), it represents a significant product advancement that would affect investor assessment of the company's competitive positioning and market opportunity in the growing data-center battery storage sector.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 7.01
The filing discloses the appointment of Jeff Hopmayer to MDWerks' Board of Directors, effective June 26, 2026. The press release (Exhibit 99.1) emphasizes Hopmayer's appointment as a pivotal addition to the board during a critical commercial inflection point, highlighting his experience in building and scaling businesses and his role in corporate strategy, partnerships, and M&A. This is a clear executive appointment event, material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-10
ENvue Medical received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a prior reverse stock split, and while it intends to request a hearing to appeal, there is no assurance of success. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-10
The 6-K discloses results of a general meeting of shareholders held on June 30, 2026, with detailed voting tallies for eight proposals: reappointment of six directors (Justin Floyd, Hans Kunz, Nikolaus Senn, Soumaya Hamzaoui, David Bolocan, Prem Parameswaran), reappointment of auditor PKF Littlejohn LLP, and adoption of annual financial statements for the year ended December 31, 2025. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the director and auditor reappointments are material governance matters affecting investor assessment of board composition and audit oversight.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-10
EX-99.1
The Company received a Staff Delisting Determination from Nasdaq on July 7, 2026, notifying it of Nasdaq's determination to delist the Company's securities pursuant to Nasdaq Listing Rule IM-5101-4. The Company intends to appeal by requesting an oral hearing before the Nasdaq Hearings Panel, with no assurance the Panel will find the Company in compliance with listing standards. This is a direct delisting notice triggering the appeal process under Rule 5815.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-10
The filing discloses under Item 4.01 that Ainos, Inc. dismissed YCM CPA INC. as its independent registered public accounting firm on July 9, 2026, and simultaneously engaged DLEE Accountancy, Inc. as the new auditor. The company explicitly states there were no disagreements with YCM and no reportable events, indicating a routine auditor transition. This is a classic auditor change event material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-10
Item 5.02
Min Chul Park, Ph.D., an independent director and member of two Board committees, resigned effective immediately on July 8, 2026. While the Item 5.02 section also discloses voluntary compensation reductions by the CEO and CFO and explores cost-cutting measures including potential asset divestitures and workforce reductions, the primary disclosed action in the Item 5.02 section is Dr. Park's departure from his director and committee positions. The resignation is material as it represents a change in board composition during a period of financial stress and capital-raising efforts.
View raw filing on EDGAR →